Contrasting the impact of cytotoxic and cytostatic drug therapies on tumour progression

Show full item record



Permalink

http://hdl.handle.net/10138/310598

Citation

Anttila , J V , Shubin , M , Cairns , J , Borse , F , Guo , Q , Mononen , T , Vazquez-Garcia , I , Pulkkinen , O & Mustonen , V 2019 , ' Contrasting the impact of cytotoxic and cytostatic drug therapies on tumour progression ' , PLoS Computational Biology , vol. 15 , no. 11 , 1007493 . https://doi.org/10.1371/journal.pcbi.1007493

Title: Contrasting the impact of cytotoxic and cytostatic drug therapies on tumour progression
Author: Anttila, Jani V.; Shubin, Mikhail; Cairns, Johannes; Borse, Florian; Guo, Qingli; Mononen, Tommi; Vazquez-Garcia, Ignacio; Pulkkinen, Otto; Mustonen, Ville
Contributor: University of Helsinki, Organismal and Evolutionary Biology Research Programme
University of Helsinki, Department of Computer Science
University of Helsinki, Organismal and Evolutionary Biology Research Programme
University of Helsinki, Organismal and Evolutionary Biology Research Programme
University of Helsinki, Organismal and Evolutionary Biology Research Programme
University of Helsinki, Organismal and Evolutionary Biology Research Programme
University of Helsinki, Department of Computer Science
University of Helsinki, Organismal and Evolutionary Biology Research Programme
Date: 2019-11-18
Language: eng
Number of pages: 18
Belongs to series: PLoS Computational Biology
ISSN: 1553-734X
URI: http://hdl.handle.net/10138/310598
Abstract: A tumour grows when the total division (birth) rate of its cells exceeds their total mortality (death) rate. The capability for uncontrolled growth within the host tissue is acquired via the accumulation of driver mutations which enable the tumour to progress through various hallmarks of cancer. We present a mathematical model of the penultimate stage in such a progression. We assume the tumour has reached the limit of its present growth potential due to cell competition that either results in total birth rate reduction or death rate increase. The tumour can then progress to the final stage by either seeding a metastasis or acquiring a driver mutation. We influence the ensuing evolutionary dynamics by cytotoxic (increasing death rate) or cytostatic (decreasing birth rate) therapy while keeping the effect of the therapy on net growth reduction constant. Comparing the treatments head to head we derive conditions for choosing optimal therapy. We quantify how the choice and the related gain of optimal therapy depends on driver mutation, metastasis, intrinsic cell birth and death rates, and the details of cell competition. We show that detailed understanding of the cell population dynamics could be exploited in choosing the right mode of treatment with substantial therapy gains. Author summary Cells and organisms evolve to better survive in their environments and to adapt to new challenges. Such dynamics manifest in a particularly problematic way with the evolution of drug resistance, which is increasingly recognized as a key challenge for global health. Thus, developing therapy paradigms that factor in evolutionary dynamics is an important goal. Using a minimal mathematical model of a cancer cell population we contrast cytotoxic (increasing death rate) and cytostatic (decreasing birth rate) treatments while keeping the effect of the therapy on the net growth reduction constant. We then quantify how the choice and the related gain of optimal therapy depends on driver mutation, metastasis, intrinsic cell birth and death rates and the details of cell competition. Most importantly, we identify specific cell population dynamics under which a certain treatment could be significantly better than the alternative.
Subject: CANCER
EVOLUTION
RESISTANCE
HETEROGENEITY
DYNAMICS
3122 Cancers
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
journal.pcbi.1007493.pdf 1.233Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record